A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).

cetrelimab (JNJ-63723283) - J&J

tolododekin alfa (ANK-101) - Ankyra Therap

https://www.asco.org/abstracts-presentations/266782

Thomas Marron; Prantesh Jain; Michael Pritchett; Nikhil Shukla; Tarik Hadid; Jun Zhang; Estelamari Rodriguez; Gail Iodice; Joseph Elassal; Howard Kaufman

Apr 21, 2026